The product is intended for minimally invasive surgical procedures in pelvic floor procedures in women.
Biomedix Incubator Ltd. (TASE:BMDX) portfolio company Endogun Medical Systems Ltd. has obtained US Food and Drug Administration (FDA) approval for its internal soft-tissue fastening solution. The product is intended for minimally invasive surgical procedures in pelvic floor procedures in women, to replace current invasive procedures.
Endogun has already obtained both FDA and EU CE Mark approval for its Endofast Reliant, a device for closing and securing internal tissue during surgery. The product is designed for use in pelvic floor reconstruction in women and to treat stress urinary incontinence. The company licensed its EndoFast ReliantBladder Fixator to US firm Cook Medical Inc. in August 2007.
Endogun is a graduate of Meytag Technology Incubator in which Biomedix owns a 28% stake.
Published by Globes [online], Israel business news - www.globes-online.com - on April 27, 2008
© Copyright of Globes Publisher Itonut (1983) Ltd. 2008